Exact Mass: 567.2185142000001
Exact Mass Matches: 567.2185142000001
Found 74 metabolites which its exact mass value is equals to given mass value 567.2185142000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
GalNAcGlcNAcThrNAc
[Chemical] Source; sea squirt H-antigen (limited periodate oxide)
N-(2,5,12-dimethoxy-3,11,16-trimethyl-1,4,10,13-tetraoxo-1,5,6,7,9,10,13,14,14a,15-decahydro-4H-6,15-epiazano-benzo[4,5]azocino[1,2-b]isoquinolin-9-ylmethyl)-2-oxo-propionamide|Saframycin C
C29H33N3O9 (567.2216688000001)
Cys Pro Trp Tyr
C28H33N5O6S (567.2151438000001)
Cys Pro Tyr Trp
C28H33N5O6S (567.2151438000001)
Cys Trp Pro Tyr
C28H33N5O6S (567.2151438000001)
Cys Trp Tyr Pro
C28H33N5O6S (567.2151438000001)
Cys Tyr Pro Trp
C28H33N5O6S (567.2151438000001)
Cys Tyr Trp Pro
C28H33N5O6S (567.2151438000001)
Glu Glu Gln Tyr
Glu Glu Tyr Gln
Glu Gln Glu Tyr
Glu Gln Tyr Glu
Glu Tyr Glu Gln
Glu Tyr Gln Glu
Met Met Thr Trp
C25H37N5O6S2 (567.2185142000001)
Met Met Trp Thr
C25H37N5O6S2 (567.2185142000001)
Met Thr Met Trp
C25H37N5O6S2 (567.2185142000001)
Met Thr Trp Met
C25H37N5O6S2 (567.2185142000001)
Met Trp Met Thr
C25H37N5O6S2 (567.2185142000001)
Met Trp Thr Met
C25H37N5O6S2 (567.2185142000001)
Pro Cys Trp Tyr
C28H33N5O6S (567.2151438000001)
Pro Cys Tyr Trp
C28H33N5O6S (567.2151438000001)
Pro Trp Cys Tyr
C28H33N5O6S (567.2151438000001)
Pro Trp Tyr Cys
C28H33N5O6S (567.2151438000001)
Pro Tyr Cys Trp
C28H33N5O6S (567.2151438000001)
Pro Tyr Trp Cys
C28H33N5O6S (567.2151438000001)
Gln Glu Glu Tyr
Gln Glu Tyr Glu
Gln Tyr Glu Glu
Thr Met Met Trp
C25H37N5O6S2 (567.2185142000001)
Thr Met Trp Met
C25H37N5O6S2 (567.2185142000001)
Thr Trp Met Met
C25H37N5O6S2 (567.2185142000001)
Trp Cys Pro Tyr
C28H33N5O6S (567.2151438000001)
Trp Cys Tyr Pro
C28H33N5O6S (567.2151438000001)
Trp Met Met Thr
C25H37N5O6S2 (567.2185142000001)
Trp Met Thr Met
C25H37N5O6S2 (567.2185142000001)
Trp Pro Cys Tyr
C28H33N5O6S (567.2151438000001)
Trp Pro Tyr Cys
C28H33N5O6S (567.2151438000001)
Trp Thr Met Met
C25H37N5O6S2 (567.2185142000001)
Trp Tyr Cys Pro
C28H33N5O6S (567.2151438000001)
Trp Tyr Pro Cys
C28H33N5O6S (567.2151438000001)
Tyr Cys Pro Trp
C28H33N5O6S (567.2151438000001)
Tyr Cys Trp Pro
C28H33N5O6S (567.2151438000001)
Tyr Glu Glu Gln
Tyr Glu Gln Glu
Tyr Pro Cys Trp
C28H33N5O6S (567.2151438000001)
Tyr Pro Trp Cys
C28H33N5O6S (567.2151438000001)
Tyr Gln Glu Glu
Tyr Trp Cys Pro
C28H33N5O6S (567.2151438000001)
Tyr Trp Pro Cys
C28H33N5O6S (567.2151438000001)
Phenyl 3-azido-3-deoxy-2,4,6-tris-O-(phenylmethyl)-1-thio-beta-D-glucopyranoside
Phenyl 4-azido-4-deoxy-2,3,6-tris-O-(phenylmethyl)-1-thio-beta-D-glucopyranoside
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(2-methoxyphenyl)ethynyl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N,1-dimethyl-4-imidazolesulfonamide
C28H33N5O6S (567.2151438000001)
(1S)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-[(5-phenyl-3-isoxazolyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1R)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-[(5-phenyl-3-isoxazolyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
N-[(2S,3R,4R,5R,6R)-2-[(2S,3R,4S,5S,6R)-5-acetamido-6-[(2S,3R)-3-acetamido-4-hydroxy-1-oxobutan-2-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
GDC-6036-NH
GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research[1].
(4r,6s)-4-hydroxy-6-[(r)-[(2s,3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-n-[(3s,7r)-2-hydroxy-7-methyl-4,5,6,7-tetrahydro-3h-azepin-3-yl]-5,6-dihydro-4h-pyran-2-carboximidic acid
(4as,5s,12as)-6-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-1,4a,5,10,11,12a-hexahydroxy-8-methoxy-3,12-dioxo-4,5-dihydrotetracene-2-carboximidic acid
2-oxo-n-{[(1r,2s,10r,13r,14s)-7,14,18-trimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-4(9),6,15(20),17-tetraen-10-yl]methyl}propanamide
C29H33N3O9 (567.2216688000001)